Background and purpose: Checkpiont targeted immunotherapy in the field of solid tumor therapy has huge potential

triggering a boom in the study of immune targeted drugs. A study has provided a basis for the follow-up study of ipilimumab combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC) patients. This study counted the adverse event statistics that ipilimumab or placebo combined with paclitaxel and carboplatin as first-line therapy for the treatment of stage Ⅳ or recurrent squamous cell carcinoma to evaluate the safety of ipilimumab combined with chemotherapy in the treatment of advanced squamous cell carcinoma.

Methods: This study selected 13 patients with ECOG scores≤1 and stage Ⅳ

A

or Ⅳ

B

squamous cell carcinoma in the Shanghai Chest Hospital

Shanghai Jiao Tong University. Randomized controlled double blind trial was used in this study. The patients of experimental group were treated with ipilimumab combined with paclitaxel and carboplatin

while the patients of control group were treated with the placebo combined with paclitaxel and carboplatin. Adverse events (AEs) were counted in the process of treatment. Results: The most common AEs were the 1/2 grade AEs. Immune-related AEs (irAEs) reported in the ipilimumab group included level Ⅰ of diarrhea and pruritus

level Ⅱ of rash and pruritus and level Ⅲ of hypophysitis. Conclusion: The side effects of ipilimumab were mild

tolerable and manageable.